Association of interleukin-12 p40 gene 3′-untranslated region polymorphism and outcome of HCV infection

World Journal of Gastroenterology

Volumn 10, Issue 16, 2004, Pages 2330-2333

  Yin, Li Min ^a   Zhu, Wan Fu ^a   Wei, Lai ^c   Xu, Xiao Yuan ^b   Sun, De Gui ^d   Wang, Yan Bin ^e   Fan, Wen Mei ^a   Yu, Min ^b   Tian, Xiu Lan ^b   Wang, Qi Xin ^c   Gao, Yan ^c   Zhuang, Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d Gu'an Stn of Disease Prev/Control   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; PROTEIN P40;

3' UNTRANSLATED REGION; ADULT; AGE; ARTICLE; AUTOANALYZER; B SCAN; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE DURATION; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 4344646379     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i16.2330     Document Type: Article

References (33)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
2. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914
3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35
4. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002; 99: 15661-15668
5. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl 1): 17-24
6. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74: 583-588
7. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512
8. Montano-Loza A, Meza-Junco J, Remes-Troche JM. Pathogenesis of hepatitis C virus infection. Rev Invest Clin 2001; 53: 561-568
9. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000; 32(1 Suppl): 98-112
10. Pape GR, Gerlach TJ, Diepolder HM, Gruner N, Jung M, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6(Suppl 1): 36-40
11. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146
12. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003; 14: 361-368
13. Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, Kaklamani E, Moutsopoulos H, Loughran TP Jr, Ollier WE, Panayi GS, Lanchbury JS. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun 2000; 1: 219-224
14. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, Asano N, Kishimoto M, Tanida Y, Kakinuma T, Mitsui H, Tada Y, Wakugawa M, Torii H, Komine M, Asahina A, Tamaki K. Interleukin-12 p40 gene (1L12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30: 161-166
15. Davoodi-Semiromi A, Yang JJ, She JX. IL-12 p40 is associated with type 1 diabetes in Caucasian-American families. Diabetes 2002; 51: 2334-2336
16. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905
17. Zhu WF, Yin LM, Li P, Huang J, Zhuang H. Pathogenicity of GB virus C on virus hepatitis and hemodialysis patients. World J Gastroenterol 2003; 9: 1739-1742
18. Romani L, Puccetti P, Bistoni F. Interleukin-12 in infectious diseases. Clin Microbiol Rev 1997; 10: 611-636
19. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-276
20. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521
21. Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Darbyshire P, Wadhwa M, Dockrell H, Salmon M, Fischer A, Durandy A, Casanova JL, Kumararatne DS. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 1998; 102: 2035-2040
22. Alloza I, Heggarty S, Goris A, Graham CA, Dubois B, McDonnell G, Hawkins SA, Carton H, Vandenbroeck K. Interleukin-12 p40 polymorphism and susceptibility to multiple sclerosis. Ann Neurol 2002; 52: 524-525
23. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225-230
24. Quiroga JA, Martin J, Navas S, Carreno V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998; 178: 247-251
25. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, Sasaki Y, Kasahara A, Hori M. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584-5591
26. Zeuzem S, Hopf U, Carreno V, Diago M, Shiffman M, Grune S, Dudley FJ, Rakhit A, Rittweger K, Yap SH, Koff RS, Thomas HC. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 1999; 29: 1280-1287
27. O'Brien CB, Moonka DK, Henzel BS, Caufield M, DeBruin MF. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. Am J Gastroenterol 2001; 96: 2473-2479
28. Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, Carithers RL, McHutchison JG, Olek E, Debruin MF. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003; 37: 1368-1374
29. Zeuzem S, Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-188
30. Barth H, Klein R, Berg PA, Wiedenmann B, Hopf U, Berg T. Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection. Hepatogastroenterology 2003; 50: 201-206
31. Lee JH, Teuber G, von Wagner M, Roth WK, Zeuzem S. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. J Med Virol 2000; 60: 264-268
32. Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Dabadghao P, Werther G, Tait BD, Harrison LC, Colman PG. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet 2001; 27: 218-221
33. Seegers D, Zwiers A, Strober W, Pena AS, Bouma G. A TaqI polymorphism in the 3′UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun 2002; 3: 419-423